Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Critical Factors of Fill Finish Manufacturing For Biologics | Contract Pharma

What are you searching for?

Sign in
White Papers / Tech Papers

Critical Factors of Fill Finish Manufacturing For Biologics

The bulk drug substance, formulation, and sterile filtering and filling of the final drug product all require special handling procedures.

Released By Ajinomoto Bio-Pharma Services

With the explosion of the biologics market, which now accounts for an estimated 20% of all pharmaceutical sales, the industry has entered a new era of drug development. This growth — 10% to 15% each year — is being driven by monoclonal antibodies, which are anticipated to have worldwide sales of nearly $125 billion by 20201. However, this burgeoning market comes with some considerable challenges for drug manufacturers, due to the fragile nature and instability of these large, complex molecules. Specifically, their need to be handled differently than small molecule drugs is forcing changes at nearly every level of manufacturing. The bulk drug substance, formulation, and sterile filtering and filling of the final drug product all require special handling procedures.

DOWNLOAD TO LEARN MORE >>>>

Download White Papers / Tech Papers Now

Download White Papers / Tech Papers Now

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters